Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	47.05	61.64	9.74	15.56
Short-Term Investments	62.98	12.02	0.25	0.55
Cash & Short-Term Investments	110.03	73.66	9.99	16.11
Cash Growth	49.36%	637.44%	-37.98%	-
Prepaid Expenses	1.86	0.47	0.25	0.32
Other Current Assets	-	-	0.13	0.07
Total Current Assets	111.89	74.14	10.37	16.49
Property, Plant & Equipment	0.36	0.74	0.16	0.25
Other Long-Term Assets	4.94	2.64	0.01	0.01
Total Assets	117.18	77.51	10.54	16.76
Accounts Payable	2.07	2.3	1.04	0.26
Accrued Expenses	8.04	2.29	0.24	0.24
Current Portion of Leases	0.44	0.34	0.11	0.1
Total Current Liabilities	10.55	4.93	1.38	0.6
Long-Term Leases	-	0.44	0.05	0.16
Other Long-Term Liabilities	-	0.03	0	0.02
Total Liabilities	10.55	5.39	1.43	0.78
Additional Paid-In Capital	222.47	3.68	2.94	2.61
Retained Earnings	-115.92	-58.33	-37.74	-30.53
Comprehensive Income & Other	0.08	-	-	-
Total Common Equity	106.63	-54.64	-34.8	-27.92
Shareholders' Equity	106.63	72.11	9.1	15.98
Total Liabilities & Equity	117.18	77.51	10.54	16.76
Total Debt	0.44	0.78	0.16	0.26
Net Cash (Debt)	109.59	72.88	9.83	15.84
Net Cash Growth	50.36%	641.67%	-37.97%	-
Net Cash Per Share	5.58	18.24	2.48	4.07
Filing Date Shares Outstanding	21.82	21.7	3.97	3.89
Total Common Shares Outstanding	21.82	4.07	3.97	3.89
Working Capital	101.34	69.21	8.99	15.9
Book Value Per Share	4.89	-13.44	-8.77	-7.18
Tangible Book Value	106.63	-54.64	-34.8	-27.92
Tangible Book Value Per Share	4.89	-13.44	-8.77	-7.18

Source: S&P Capital IQ. Standard template. Financial Sources.